Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Adamas Pharma (ADMS)

Adamas Pharma (ADMS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 376,369
  • Shares Outstanding, K 45,787
  • Annual Sales, $ 74,460 K
  • Annual Income, $ -57,400 K
  • 60-Month Beta 2.82
  • Price/Sales 5.02
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade ADMS with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.70
  • Most Recent Earnings N/A on 11/10/21
  • Next Earnings Date 11/11/21
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/21
See More
  • Average Estimate -0.17
  • Number of Estimates 5
  • High Estimate -0.10
  • Low Estimate -0.26
  • Prior Year -0.64
  • Growth Rate Est. (year over year) +73.44%

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.00 +2.75%
on 10/25/21
8.25 -0.36%
on 11/23/21
+0.21 (+2.62%)
since 10/22/21
3-Month
4.41 +86.39%
on 08/27/21
8.25 -0.36%
on 11/23/21
+3.59 (+77.54%)
since 08/23/21
52-Week
4.02 +104.48%
on 08/16/21
9.15 -10.16%
on 02/01/21
+3.93 (+91.61%)
since 11/23/20

Most Recent Stories

More News
Supernus Pharmaceuticals Completes Acquisition of Adamas Pharmaceuticals

Acquisition strengthens Parkinson’s disease portfolio and diversifies revenue and cash flow...

SUPN : 29.99 (-0.03%)
ADMS : 8.22 (+0.74%)
Supernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Adamas Pharmaceuticals Tender Offer

ROCKVILLE, Md., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) today announced that the required waiting period under...

SUPN : 29.99 (-0.03%)
ADMS : 8.22 (+0.74%)
Adamas: Q3 Earnings Snapshot

EMERYVILLE, Calif. (AP) _ Adamas Pharmaceuticals Inc. (ADMS) on Wednesday reported a loss of $19.5 million in its third quarter.

ADMS : 8.22 (+0.74%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates FTSI, UMPQ, FLXN, ADMS; Shareholders are Encouraged to Contact the Firm

/PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: FTS International, Inc. (NYSE:...

UMPQ : 17.66 (-1.73%)
FLXN : 9.12 (-0.22%)
ADMS : 8.22 (+0.74%)
FTSI : 26.49 (-0.15%)
SHAREHOLDER ALERT: WeissLaw LLP Reminds ADMS, FLXN, AZPN, and EBMT Shareholders About Its Ongoing Investigations

/PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this...

ADMS : 8.22 (+0.74%)
FLXN : 9.12 (-0.22%)
AZPN : 188.96 (-1.18%)
EBMT : 14.49 (+1.14%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates UMPQ, XLRN, ADMS, AZPN; Shareholders are Encouraged to Contact the Firm

NEW YORK, NY / ACCESSWIRE / October 21, 2021 / Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Umpqua Holdings Corporation (NASDAQ:UMPQ) concerning...

UMPQ : 17.66 (-1.73%)
XLRN : 178.75 (-0.52%)
ADMS : 8.22 (+0.74%)
AZPN : 188.96 (-1.18%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates KRA, EBMT, ESBK, ADMS; Shareholders are Encouraged to Contact the Firm

/PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Kraton Corporation (NYSE: KRA)...

KRA : 46.49 (+0.02%)
EBMT : 14.49 (+1.14%)
ESBK : 23.08 (+0.04%)
ADMS : 8.22 (+0.74%)
SHAREHOLDER ALERT: WeissLaw LLP Reminds ADMS, FLXN, AZPN, and EBMT Shareholders About Its Ongoing Investigations

/PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this...

ADMS : 8.22 (+0.74%)
FLXN : 9.12 (-0.22%)
AZPN : 188.96 (-1.18%)
EBMT : 14.49 (+1.14%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates ADMS, FLXN, ACBI, SQ; Shareholders are Encouraged to Contact the Firm

/PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Adamas Pharmaceuticals, Inc....

ADMS : 8.22 (+0.74%)
FLXN : 9.12 (-0.22%)
ACBI : 32.34 (-0.09%)
SQ : 67.88 (-0.54%)
ADAMAS PHARMACEUTICALS INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Adamas Pharmaceuticals, Inc. - ADMS

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Adamas Pharmaceuticals, Inc. (NasdaqGM: ADMS)...

ADMS : 8.22 (+0.74%)

Business Summary

Adamas Pharmaceuticals, Inc. is a specialty pharmaceutical company driven to improve the lives of those affected by chronic disorders of the central nervous system. The company seeks to achieve this by modifying the pharmacokinetic profiles of approved drugs to create novel therapeutics for use alone...

See More

Key Turning Points

3rd Resistance Point 8.32
2nd Resistance Point 8.29
1st Resistance Point 8.25
Last Price 8.22
1st Support Level 8.18
2nd Support Level 8.15
3rd Support Level 8.11

See More

52-Week High 9.15
Last Price 8.22
Fibonacci 61.8% 7.19
Fibonacci 50% 6.59
Fibonacci 38.2% 5.98
52-Week Low 4.02

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar